Procyanidin B2

Procyanidin B2

SCHEMBL718738

Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@@H](O)[C@@H]2c1c(O)cc(O)c2c1O[C@H](c1ccc(O)c(O)c1)[C@H](O)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 3/20 1.00
HSD17B10 Q99714 3/20 1.00
ALOX15 P16050 2/20 1.00
CYP1A2 P05177 1/20 1.00
MMP2 P08253 4/20 0.98
MMP9 P14780 4/20 0.98
PRKD3 O94806 3/20 0.98
PRKCG P05129 3/20 0.98
PRKCB P05771 3/20 0.98
PRKCA P17252 3/20 0.98
PRKCH P24723 3/20 0.98
PRKCI P41743 3/20 0.98
PRKCE Q02156 3/20 0.98
PRKCQ Q04759 3/20 0.98
PRKCZ Q05513 3/20 0.98
PRKCD Q05655 3/20 0.98
PRKD1 Q15139 3/20 0.98
PTGS1 P23219 2/20 0.94
PDE4D Q08499 1/20 0.67
BACE1 P56817 4/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Procyanidin B2 SCHEMBL677697 1.00 SNCA (1.00) SNCAHSD17B10ALOX15CYP1A2MMP2
Procyanidin B2 SCHEMBL15142352 1.00 SNCA (1.00) SNCAHSD17B10ALOX15CYP1A2MMP2
Procyanidin B2 SCHEMBL18685718 1.00 SNCA (1.00) SNCAHSD17B10ALOX15CYP1A2MMP2
Procyanidin B2 SCHEMBL14626386 1.00 SNCA (1.00) SNCAHSD17B10ALOX15CYP1A2MMP2
Procyanidin B2 SCHEMBL14339427 1.00 SNCA (1.00) SNCAHSD17B10ALOX15CYP1A2MMP2
Procyanidin B2 SCHEMBL23251016 1.00 SNCA (1.00) SNCAHSD17B10ALOX15CYP1A2MMP2
Procyanidin B2 SCHEMBL14413656 1.00 SNCA (1.00) SNCAHSD17B10ALOX15CYP1A2MMP2
Procyanidin B2 SCHEMBL20661403 1.00 SNCA (1.00) SNCAHSD17B10ALOX15CYP1A2MMP2
Procyanidin B2 SCHEMBL22043665 1.00 SNCA (1.00) SNCAHSD17B10ALOX15CYP1A2MMP2
Procyanidin B2 SCHEMBL13285131 1.00 SNCA (1.00) SNCAHSD17B10ALOX15CYP1A2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4408187-B1 PROANTHOCYANIDINS (CONDENSED TANNINS) AS NUTRIENT FOR HONEY BEES Apix Biosciences (BE) 2026-03-04 EP claimed
EP-4696145-A2 PROANTHOCYANIDINS (CONDENSED TANNINS) AS NUTRIENT FOR HONEY BEES APIX BIOSCIENCES (BE) 2026-02-18 EP claimed
WO-2025064839-A1 COMPOSITIONS AND METHODS RELATED TO THE SIMULTANEOUS MANUFACTURE AND PURIFICATION OF FLAVOR AND FRAGRANCE MOLECULES Natural Extraction Systems, LLC (US) 2025-03-27 WO claimed
CN-119607150-A Deep eutectic solvent and preparation method and application thereof 天津中医药大学 2025-03-14 CN claimed
EP-4493552-A2 COMPOSITIONS AND METHODS RELATED TO THE SIMULTANEOUS MANUFACTURE AND PURIFICATION OF FLAVOR AND FRAGRANCE MOLECULES Natural Extraction Systems, LLC (US) 2025-01-22 EP claimed
CN-118914413-B Ultra-high performance liquid chromatography-tandem mass spectrometry method for simultaneously detecting 39 kinds of anthocyanin in litchi 海南省农业科学院三亚研究院(海南省实验动物研究中心) 2024-12-03 CN claimed
CN-118914413-A Ultra-high performance liquid chromatography-tandem mass spectrometry method for simultaneously detecting 39 kinds of anthocyanin in litchi 海南省农业科学院三亚研究院(海南省实验动物研究中心) 2024-11-08 CN claimed
WO-2024175614-A1 STABLE LIQUID FORMULATIONS COMPRISING (6S)-5-METHYLTETRAHYDROFOLIC ACID OR SALTS THEREOF MERCK PATENT GMBH (DE) 2024-08-29 WO claimed
US-11925194-B2 Antimicrobially active mixtures SYMRISE AG (DE) 2024-03-12 US claimed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
US-8669048-B2 Pluripotent cell lines and methods of use thereof PARKINSON'S INSTITUTE (US) 2014-03-11 US claimed
US-20120052053-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION THE PARKINSON'S INSTITUTE 2012-03-01 US claimed
CN-102245180-A Compositions and methods for the treatment of altered alpha-synuclein function PARKINSON S INST 2011-11-16 CN claimed
EP-2361089-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION Parkinson's Institute (US) 2011-08-31 EP claimed
EP-2331111-A1 ANTIOXIDANT AND PHYSICAL PERFORMANCE EFFECTS OF A GRAPE EXTRACT Naturex S.A. (FR) 2011-06-15 EP claimed
US-20100167286-A1 Pluripotent cell lines and methods of use thereof PARKINSON'S INSTITUTE (US) 2010-07-01 US claimed
WO-2010056413-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION PARKINSON'S INSTITUTE (US) 2010-05-20 WO claimed
WO-2010021935-A1 ANTIOXIDANT AND PHYSICAL PERFORMANCE EFFECTS OF A GRAPE EXTRACT NATUREX S.A. (FR) 2010-02-25 WO claimed
US-20100047372-A1 ANTIOXIDANT AND PHYSICAL PERFORMANCE EFFECTS OF A GRAPE EXTRACT Naturex, S.A. 2010-02-25 US claimed
WO-2010008486-A2 PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF PARKINSONS INSTITUTE (US) 2010-01-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052053-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION SNCA, PARK7, NLN SNCA 1/4885HSD17B10 638/4885ALOX15 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.